CRISPR Gene Editing Therapies Market

CRISPR Gene Editing Therapies Market by Type of Therapy, Therapeutic Approach, Therapeutic Area and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    93

  • Pages
    217

  • View Count
    12403

CRISPR Gene Editing Therapies Market Overview

The CRISPR gene editing therapies market is estimated to be worth $35 million in 2024 and is expected to grow at CAGR of 129% during the forecast period. Clustered regularly interspaced short palindromic repeats (CRISPR) are a family of DNA sequences, which constitute a primitive immune system that is responsible for protecting prokaryotic cells from phage infections. It was first described in 1987, however, its potential as a gene editing tool was not realized until 2012. Since then, the CRISPR revolution has not shown any signs of slowing down and has been responsible for significant advances in molecular biology and therapy development. Fundamentally, the CRISPR/Cas system involves specific palindromic DNA sequences which work in tandem with a family of caspase enzymes (Cas9, Cas12), in order to excise gene fragments with high precision. Compared to the other targeted nuclease-based systems, CRISPR is relatively faster, and cost-efficient; as a result, the demand for this gene editing tool is very high. The relatively recent discovery / development of novel accompanying nucleases, namely Cas12a, Cas13, Cas14 and dCas9, has significantly improved the precision of this technology. Presently, there are several companies using different variants of the CRISPR/Cas technology for basic research, and the development of gene editing solutions. However, the therapeutic use of this versatile genetic manipulation tool is only being investigated by a select few stakeholders in the pharmaceutical industry. The aforementioned scenario is attributed to the surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to three leading players, namely Editas Medicine, CRISPR Therapeutics and Intellia Therapeutics, in the contemporary market.

Clinical trials of CRISPR gene editing therapies are currently focused mainly on oncological and hematological disorders; however, several CRISPR drug product candidates against certain neurological disorders and infectious diseases, specifically targeting recurrent conditions, are under investigation. Post 2014, the overall interest in CRISPR gene editing technology has grown exponentially, with several start-ups entering the market and 6 of the top 10 pharmaceutical companies restructuring their efforts in this direction. Over time, a substantial body of evidence has also been generated validating the therapeutic applications of CRISPR gene editing technology, which has, in turn, prompted the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and has caused investors to put in significant capital into innovator companies involved in CRISPR gene editing therapies market, over the last two years alone. In fact, the three leading companies in this industry segment together have combined market capitalization of more than USD 10 billion, and have raised more than USD 2.8 billion in various funding rounds. Despite the possibly limitless potential of the CRISPR/Cas technology, further investigation, probing its safety and therapeutic efficacy in large diverse populations, is required. Key impediments to approval and other existing challenges that are being addressed by stakeholders, include off-target toxicity-related concerns and complexities related to the delivery of CRISPR components into target cells. Concerning delivery, innovators in this field have reported notable success using different types of platforms for facilitating the intracellular administration of CRISPR components; examples of successful delivery methods include electroporation, AAV vectors and lipid nanoparticles (LNPs). A few companies are also evaluating bacteriophages as a potential delivery system for such products. Promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to push CRISPR drug pipeline to higher phases and on to commercialization. We believe that the CRISPR gene editing therapies market is likely to witness a commendable market growth during the forecast period.

Context of CRISPR Gene Editing Therapies Market List of CRISPR based Therapeutics in CRISPR Gene Editing Therapies Market Start up Health Indexing in CRISPR Gene Editing Therapies Market

Key Companies in CRISPR Gene Editing Therapies Market

Examples of key companies engaged in CRISPR gene editing therapies market (which have also been profiled in this market report; the complete list of companies is available in the full report) include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Excision BioTherapeutics, Locus Biosciences, Graphite Bio, Emendo Biotherapeutics (A Subsidiary of AnGes), Beam Therapeutics, Modalis Therapeutics and Refuge Biotechnologies. This gene editing therapies market report includes an easily searchable excel database of all the companies using Crispr Cas9 gene editing to develop therapeutics, worldwide.

Recent Developments in CRISPR Gene Editing Therapies Market:

Several recent developments have taken place in the field of CRISPR gene editing therapies market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, GenScript Biotech entered into a strategic agreement with T-MAXIMUM Biotech with an aim to develop CAR T cell therapy by using GenScript's CRISPR nucleic acid reagents. 
  • In June 2023, researchers at MIT and the Broad Institute of MIT and Harvard identified a novel RNA-guided gene editing system in eukaryotes. According to the researchers, the new gene editing system has the potential to deliver foreign genes much efficiently as compared to the CRISPR-Cas systems. 
  • In June 2023, Pairwise announced the launch of its CRISPR enhanced food product line, Conscious Greens. The company claims that the gene edited super greens have a better taste profile with more nutritional value.

Scope of the Report

The “CRISPR Gene Editing Therapies Market, 2021-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the CRISPR gene editing therapies market. The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in CRISPR gene editing therapies market, across different geographies.

Big Pharma Players Analysis in CRISPR Gene Editing Therapies Market Patent Analysis in CRISPR Gene Editing Therapies Market Funding and Investment Analysis in CRISPR Gene Editing Therapies Market

Amongst other elements, the market research report includes:

  • A review of the CRISPR based therapeutics that are currently in different stages of development. It features a detailed analysis of pipeline molecules, based on several relevant parameters, such as target therapeutic area (autoimmune disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others), phase of development (discovery, preclinical and clinical), approach of therapy (ex vivo and in vivo), cell source (autologous and allogeneic), type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), and the type of technology used. It also includes information on the completed, ongoing and planned clinical trials for CRISPR based therapeutics, sponsored by various industry players.
  • Elaborate profiles of key players in CRISPR gene editing therapies market. Each company profile features a brief overview of the company, its financial information (if available), a brief description of its therapeutic candidates, recent developments, and an informed future outlook.
  • An in-depth analysis of around 2,000 patents related to CRISPR technology that have been filed / granted, since 2015, highlighting the key trends associated with these patents, across type of patent, publication year and application year, regional applicability, IPCR symbols, emerging focus areas, inventor information, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.  
  • An analysis of the partnerships that have been inked by various stakeholders engaged in the development of CRISPR based therapeutics, during the period 2014-2020, covering research and licensing agreements, R&D agreements, licensing agreements, licensing and manufacturing agreement, product development and manufacturing agreements, joint ventures and other types of partnership deals.
  • An analysis of the investments made at various stages of development of the companies engaged in CRISPR gene editing therapies market, covering instances of seed financing, venture capital financing, grants / awards, capital raised from IPOs and subsequent offerings.
  • An analysis of the start-ups (established in the time period between 2013-2020 and have less than 200 employees) engaged in the development of CRISPR based therapeutics, based on several parameters, such as number of candidates in discovery, preclinical and clinical phase of development, therapeutic area, amount raised through funding, number of investors, type of funding, number of deals signed, and number of patents filed.

The key objective of CRISPR gene editing therapies market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for CRISPR gene editing therapies market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the forecast period 2021-2030. For this purpose, we have segmented the future opportunity across [A] target therapeutic area (hematological disorders, oncological disorders, ophthalmic diseases, infectious diseases and others) [B] approach of therapy (ex vivo and in vivo), [C] type of therapy (CAR-T cell therapy, HSC therapy, T cell therapy, and TIL), [D] key geographical regions (North America, Europe and Asia-Pacific). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.

Frequently Asked Questions

Question 1: What is gene editing?

Answer: Gene editing, or genome gene editing, is a genetic engineering technique involving DNA insertion, deletion, modification or replacement in the targeted genome sequence of a living organism.

Question 2: How big is the CRISPR gene editing therapies market?

Answer: The CRISPR gene editing therapies market size is estimated to be worth $35 million in 2025.

Question 3: What is the projected market growth of the CRISPR gene editing therapies market?

Answer: The CRISPR gene editing therapies market is expected to grow at compounded annual growth rate (CAGR) of 129% during the forecast period.

Question 4: Who are the leading companies in the CRISPR gene editing therapies market?

Answer: Examples of key drug developers engaged in CRISPR gene editing therapies market (which have also been profiled in this market report; the complete list of companies is available in the full report) include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Excision BioTherapeutics, Locus Biosciences, Graphite Bio, Emendo Biotherapeutics (A Subsidiary of AnGes), Beam Therapeutics, Modalis Therapeutics and Refuge Biotechnologies.

Question 5: How many companies are currently engaged in the CRISPR gene editing therapies market?

Answer: Over 40 companies are currently engaged in the CRISPR gene editing therapies market to develop and produce novel CRISPR based therapeutics.

Question 6: How many partnership deals have been inked between the players engaged in CRISPR gene editing therapies market?

Answer: More than 65 partnership deals have been inked between the players engaged in CRISPR gene editing therapies market, highlighting the consolidation efforts of the stakeholders in this industry.

Question 7: How much money has been invested by stakeholders in the CRISPR gene editing therapies market?

Answer: More than USD 5 billion has been invested by stakeholders in the CRISPR gene editing therapies market, highlighting the growing interest of players in CRISPR gene editing therapies industry.

Question 8: When is the first CRISPR/Cas9 therapy approval expected?

Answer: CRISPR Therapeutics drug exa-cel is expected to be the first CRSIPR/Cas9 therapy to receive approval in late 2023 / early 2024.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com